Premium
Current thinking on the mechanistic basis of Alzheimer's and implications for drug development
Author(s) -
Ising C,
Stanley M,
Holtzman DM
Publication year - 2015
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.200
Subject(s) - dementia , disease , neuroscience , drug development , alzheimer's disease , drug , medicine , amyloid (mycology) , amyloid β , tau protein , psychology , pharmacology , pathology
Alzheimer disease (AD) is the most common cause of dementia and is characterized by the aggregation and accumulation of two proteins in the brain, amyloid‐β (Aβ) and tau. Aβ and tau begin to buildup 15‐20 years before the clinical onset of AD dementia. Increasing evidence suggests that preventing or decreasing the amount of aggregated forms of both Aβ and tau in the brain can serve as potential disease‐modifying treatments for AD.